Genfit S.A. (NASDAQ:GNFT) Short Interest Update

Genfit S.A. (NASDAQ:GNFT) was the target of a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 67,800 shares, an increase of 16.5% from the September 15th total of 58,200 shares. Based on an average trading volume of 10,700 shares, the days-to-cover ratio is currently 6.3 days. Currently, 0.1% of the shares of the stock are sold short.

Genfit Price Performance

Shares of Genfit stock traded up $0.37 during midday trading on Wednesday, hitting $6.28. 35,695 shares of the company were exchanged, compared to its average volume of 17,429. The firm has a 50 day simple moving average of $4.71 and a 200-day simple moving average of $4.31. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74. Genfit has a 52 week low of $2.97 and a 52 week high of $6.29.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Genfit in a research report on Friday, October 11th.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.